Journal of Kidney Cancer and VHL 2023-01-16T15:23:18+00:00 ​Dr. Ulka Vaishampayan Open Journal Systems <p>Journal of Kidney Cancer and VHL (ISSN: 2203-5826) is indexed in <strong>PubMed</strong>,&nbsp;Emerging Sources Citation Index&nbsp;of <strong>Web of Science</strong>, and the Directory of Open Access Journals (<strong>DOAJ</strong>). Journal is dedicated for the dissemination of research findings in kidney cancer and VHL.</p> Ligustrazine Inhibits the Migration and Invasion of Renal Cell Carcinoma 2022-03-25T02:22:06+00:00 Xufeng Zhang Junfu Wang Yanhua Cao Kalin Li Chao Sun Wen Jiang Qian Xin Jue Wang Tonggang Qi Shuangde Liu Yun Luan <p>Ligustrazine is a Chinese herb (<em>Chuanxiong)</em> approved for use as a medical drug in China. Recent evidence suggests that ligustrazine has promising antitumor properties. Our preliminary results showed that ligustrazine could inhibit the growth of human renal cell carcinoma (RCC) cell lines. However, the complicated molecular mechanism has not been fully revealed. Therefore, the purpose of this study to investigate the mechanism of ligustrazine resistance in human RCC cells. Cell proliferation, migration, invasion, and colony-formation ability of RCC cells A498 were detected by MTT assay, clonal formation rates, and transwell chamber assay in <em>vitro</em>. The expression of epithelial–mesenchymal transition (EMT)–related proteins were analyzed using western blot test. The effect of ligustrazine on the growth of A498 cells in nude mice was investigated in <em>vivo</em>. Our results showed that ligustrazine could significantly inhibit the proliferation, migration, and invasion of A498 both in <em>vivo</em> and <em>vitro</em>. Western blot analysis showed that the expressions of EMT-related, N-cadherin, snail, and slug proteins were significantly decreased in A498 in the ligustrazine treatment group. This study indicated that ligustrazine could significantly inhibit the malignant biological behaviors of RCC cell lines, possibly by inhibiting the EMT process.</p> 2023-01-14T00:00:00+00:00 Copyright (c) 2023 Xufeng Zhang, Junfu Wang, Yanhua Cao, Kailin Li, Chao Sun, Wen Jiang, Qian Xin, Jue Wang, Tonggang Qi, Shuangde Liu, Yun Luan Delayed Cardiac Metastasis from Renal Cell Carcinoma Caused by VHL Mutation 2022-11-08T01:02:22+00:00 Christopher L. Sudduth Anthony Castagno Peter Maggs <p>Cardiac metastasis caused by renal cell carcinoma (RCC) without vena caval involvement is rare. No mutation has been associated with this unique phenotype. A 77-year-old male presented to our clinic with a symptomatic right ventricular mass after nephrectomy for clear cell RCC (ccRCC). The mass was resected, and metastatic disease was confirmed. Targeted exon sequencing identified a <em>VHL</em> mutation (c.494T &gt; G, p.V165G) in the resected specimen. While more than half of ccRCC cases are associated with <em>VHL</em> mutations, this case is the first to show the association between delayed, isolated cardiac metastasis and <em>VHL</em> V165G mutation. The phenotype presented 12 years after nephrectomy and localized to the right ventricular apex. Further genomic characterization of cases with cardiac metastases may provide clues regarding unique mutations noted. Patients exhibiting delayed spread of RCC to the heart must be screened for this mutation.</p> 2023-02-07T00:00:00+00:00 Copyright (c) 2023 Christopher Sudduth, Anthony Castagno, Peter Maggs The Significance of Serum C-Reactive Protein and Neutrophil–Lymphocyte Ratio in Predicting the Diagnostic Outcomes of Renal Mass Biopsy Procedure 2022-12-22T19:12:18+00:00 Aykut Colakerol Sergen Sahin Ramazan Omer Yazar Mustafa Zafer Temiz Emrah Yuruk Engin Kandirali Atilla Semercioz Ahmet Yaser Muslumanoglu <p>This study aimed to investigate the predictive role of serum C-reactive protein (CRP) and neutrophil-to-lymphocyte ratio (NLR) on renal mass biopsy outcomes. A total of 71 patients with suspected kidney masses who underwent renal mass biopsy procedure between January 2017 and January 2021 were retrospectively evaluated. Pathological results after the procedure were obtained and pre-procedural serum CRP and NLR levels were extracted from the patients’ data. The patients were grouped into benign and malignant pathology groups according to the histopathology results. The parameters were compared between the groups. Diagnostic role of the parameters in terms of sensitivity, specificity, and positive and negative predictive values was also determined. Additionally, Pearson correlation analysis, and univariate and multivariate cox proportional hazard regression analyses were also performed to investigate the above association with tumor diameter and pathology results, respectively. At the end of the analyses, a total of 60 patients had malignant pathology on histopathological investigations of the mass biopsy specimens, whereas the remaining 11 patients had a benign pathological diagnosis. Significantly higher CRP and NLR levels were detected in the malignant pathology group. The parameters positively correlated with the malignant mass diameter, as well. Serum CRP and NLR determined the malignant masses before the biopsy with sensitivity and specificity of 76.6 and 81.8%, and 88.3 and 45.4%, respectively. Moreover, univariate and multivariate analyses showed that serum CRP level had a significant predictive value for malignant pathology (HR: 0.998, 95% CI: 0.940–0.967, P &lt; 0.001 and HR: 0.951, 95% CI: 0.936–0.966, P &lt; 0.001, respectively). In conclusion, serum CRP and NLR levels were significantly different in patients with malignant pathology after renal mass biopsy compared to the patients with benign pathology. Serum CRP level, in particular, diagnosed malignant pathologies with acceptable sensitivity and specificity values. Additionally, it had a substantial predictive role in determining the malign masses prior the biopsy. Therefore, pre-biopsy serum CRP and NLR levels may be used to predict the diagnostic outcomes of renal mass biopsy in clinical practice. Further studies with larger cohorts can prove our findings in the future.</p> 2023-02-03T00:00:00+00:00 Copyright (c) 2023 Aykut Colakerol, Sergen Sahin, Ramazan Omer Yazar, Mustafa Zafer Temiz, Emrah Yuruk, Engin Kandirali, Atilla Semercioz, Ahmet Yaser Muslumanoglu